Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q3 FY23 Earnings Presentation
15 slides from Zydus Lifesciences's earnings presentation, Feb 3, 2023
Slide 1: Cover letter to stock exchanges
zyd Dedicated To Life February 3, 2023 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dea
Slide 2: Zydus Lifesciences Limited Earnings Presentation
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation 3rd February, 2023 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q3 FY23: At a Glance
Q3 FY23: At a Glance zyd~ Dedicated To Life Revenues from Highlights of Q3 FY23 R&D Operations* '' '' ,------------------------------------------------------ '' ❑ Total revenues grew 20% yoy, led by robust growth across businesses. :' '' Rs. 43,623 mn '' '' ' ''' Rs. 3,435 mn '' ❑ India formulations
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) zyd~ Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 63.4% 61.3% 62.9% 61.4% 65.4% 43,623 40,727 41,347 28,519 36,398 38,638 25,634 25,403 23,064 23,680 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Total R&D (Rs. mn) and
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) zyd~ PAT ex. Exceptional, One-offs and Discontinued ops.(Rs. mn) Organic Capex (Rs. mn) 6,087 6,225 3,100 5,250 5,295 2,668 2,828 5,069 2,554 2,157 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Net Debt/ EBITDA Net Working Capital* (Rs. m
Slide 7: India Formulations business
India Formulations business zyd~ Dedicated To Life Sustained growth driven by robust performance across key therapies Highlights for the quarter Revenues (Rs. mn) Q3 FY23 Revenue 12,648 12,316 Contribution 10,785 11,640 11,251 ▪ The business grew by 14% YoY, ex-COVID opportunities, the growth was 16
Slide 8: Consumer Wellness
Consumer Wellness zyd~ Dedicated To Life Delivering the growth on the back of strong brand equity Highlights for the quarter Revenues (Rs. mn) Q3 FY23 Revenue Contribution ▪ Inflation, which hurt margins over the last few 6,916 quarters, is cooling down in key inputs except milk, 6,330 where it stil
Slide 9: US Formulations business
US Formulations business zyd~ Dedicated To Life Delivering sustained growth on a sequential basis Highlights for the quarter Revenues (Rs. mn) Q3 FY23 Revenue Contribution ▪ Received 14 new product approvals (incl. 3 tentative 19,250 17,084 approvals) and launched 6 new products. 14,892 15,592 14,23
Slide 10: Emerging Markets Formulations business
Emerging Markets Formulations business zyd~ Dedicated To Life Base business continued to display robust growth Highlights for the quarter Revenues (Rs. mn) Q3 FY23 Revenue Contribution ▪ The business grew by 15% YoY, excluding revenue of COVID related products from the base. - 3,155 3,308 3,078 2,91
Slide 11: Updates on Innovation
Updates on Innovation zyd~ Dedicated To Life NCE: Saroglitazar Magnesium • The molecule is undergoing Phase II(b)/ III clinical trials for PBC indication for the US market. It received approval from the MoH of Spain, Iceland and Argentina to conduct Phase II(b)/ III clinical trials for this indicati
Slide 12: Zydus at a Glance
Zydus at a Glance zyd~ Dedicated To Life >$2 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Approx. Among 1st Revenues from branded Approved product for In 60% of product 50% business (India, EM and T
Slide 13: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) zyd~ Dedicated To Life Q3 Q3 YoY Q2 QoQ 9M 9M YoY Comments for Q3 FY23 Rs. mn FY23 FY22 gr. FY23 gr. FY23 FY22 gr. Total Income from Ops. 43,623 36,398 19.8% 41,347 5.5% 1,25,697 1,14,014 10.2% • YoY growth in total income from Gross Contribution (GC) 28
Slide 14: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations zyd~ Dedicated To Life Q3 Q3 YoY 9M 9M YoY Rs. mn FY23 FY22 gr. % FY23 FY22 gr. % A. On operating transactions (above EBITDA line) -1,096 -181 -505.7% -3,639 -952 -282.3% a. Included in other operating income -1,052 -181 -481.2% -3,429 -971 -253.1% b. Included i
Slide 15: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-71800839 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C